Skip to contentpdufa.bio

Ubamatamab

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Ubamatamab is a Regeneron Pharmaceuticals Inc. program. Its next catalyst is a Readout in May 2027.

REGN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Regeneron Pharmaceuticals Inc. (REGN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · May 2027REGN

Questions

When is Ubamatamab's next FDA decision or readout?

The next tracked catalyst for Ubamatamab is a Readout in May 2027.

What happened at Ubamatamab's most recent FDA decision?

No FDA decision for Ubamatamab is in our archive yet.

Who makes Ubamatamab?

Regeneron Pharmaceuticals Inc. (REGN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.